# Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

> **NCT00813072** · PHASE2 · COMPLETED · sponsor: **PharmaEngine** · enrollment: 135 (actual)

## Conditions studied

- Stomach Neoplasms
- Esophageal Neoplasms

## Interventions

- **DRUG:** PEP02
- **DRUG:** irinotecan
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00813072
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-07
- **Final completion:** 2010-12
- **Target enrollment:** 135 (ACTUAL)
- **Last updated:** 2012-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813072, "Study of PEP02, Irinotecan or Docetaxel in Gastric or Gastroesophageal Junction Adenocarcinoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00813072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*